Evonik's Subsidiary Syneqt Seeks New Owner as BASF's €24 Bid and Ashland Talk Keep the Parent in Play

Evonik's animal-nutrition unit Syneqt has confirmed it is hunting for a new owner, a move that widens the spotlight from the parent company's takeover saga to the future shape of its individual divisions. Syneqt management spokesman Thomas Basten said the subsidiary's 3,500 jobs are not at risk, according to media reports — pairing the search for an investor with a reassuring message to staff.

The distinction matters. Syneqt's declaration describes an ongoing search, not a completed sale, and it sits on a different corporate level from the question of who might ultimately own Evonik itself. No conclusion about the parent's fate can be drawn from the subsidiary's stance.

The €24 Offer Still Sets the Frame

Behind all of this sits BASF's sweetened, unconfirmed takeover proposal of €24 per Evonik share, valuing the group at more than €11 billion, as reported by Handelsblatt. Evonik is reviewing the offer, according to the report. BASF's pledge to honor existing agreements on jobs and sites surfaced roughly a week earlier, and Syneqt's statement adds the subsidiary's perspective to that debate. Job guarantees and independence are separate matters: a commitment on employment does not answer the ownership question.

A Buyer and a Possible Target at Once

Evonik is not only fielding interest — it is also weighing a transaction of its own. Handelsblatt reported on October 22 that the company is considering a larger acquisition of U.S. chemicals group Ashland. That review is at an early stage and no deal is assured; Evonik does not comment on market rumors as a matter of policy. The report triggered downward pressure on Evonik shares that day, according to dpa-AFX, underlining how sensitive investors are to the company's various transaction options.

Should investors sell immediately? Or is it worth buying Evonik?

Product Launches Proceed in Parallel

Operationally, Evonik has kept its pipeline moving. On October 19 it introduced Lypron, a rumen-stable lysine solution for supplying amino acids to ruminants, with Sipena set to manufacture the product exclusively for Evonik. A day later, on October 20, the company launched two VESTAKEEP PEEK grades — DC4760 and DC4780 — designed for CAD/CAM processing in long-term dental prosthetics.

Evonik is also pursuing a joint recycling effort. Together with Toyotsu Chemiplas and Sanyo Chemical, it launched an initiative on October 13 for the chemical recycling of polyurethane foam in Japan, aimed at recovering polyols and amines and testing a scalable model.

These projects sit at different stages of maturity. The new products are already on the market, while the recycling effort is a feasibility study — and a launch and a pilot are not equivalent evidence of future revenue.

Evonik at a turning point? This analysis reveals what investors need to know now.

For investors, the questions split cleanly: the takeover talks concern who might own Evonik, while Lypron, the dental resins and the Japanese recycling venture concern what the company sells. Both deserve attention, but neither settles the ownership question nor proves the commercial payoff of the new offerings.

Ad

Evonik Stock: New Analysis - 28 October

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...